Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma

Seminars in Cancer Biology

Volumn 26, Issue , 2014, Pages 78-88

  Shlomai, Amir ^a   de Jong, Ype P ^a,b   Rice, Charles M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Hepatitis B virus (HBV); Hepatitis C virus (HCV); Hepatocellular carcinoma (HCC); Oncogenesis; Viral hepatitis

Indexed keywords

HEPATITIS B VIRUS X PROTEIN; JANUS KINASE; RAS PROTEIN; STAT PROTEIN; MICRORNA 122;

CANCER RISK; CHRONIC HEPATITIS; DISEASE ASSOCIATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; VIRUS DNA CELL DNA INTERACTION; VIRUS HEPATITIS; GENE PRODUCT; LIVER CARCINOGENESIS; MALIGNANT TRANSFORMATION; RISK FACTOR; VIRUS CARCINOGENESIS; VIRUS REPLICATION; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION; COMPLICATION; HEPACIVIRUS; LIVER NEOPLASMS; PHYSIOLOGY; TUMOR VIRUS; VIRUS CELL TRANSFORMATION; VIRUS INFECTION;

CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER NEOPLASMS; ONCOGENIC VIRUSES; TUMOR VIRUS INFECTIONS;

EID: 84901837328     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.01.004     Document Type: Review

References (175)

1. Arzumanyan A., Reis H.M., Feitelson M.A. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nature Reviews Cancer 2013, 13:123-135.
2. El-Serag H.B. Hepatocellular carcinoma. The New England Journal of Medicine 2011, 365:1118-1127.
3. Mittal S., El-Serag H.B. Epidemiology of hepatocellular carcinoma: consider the population. Journal of Clinical Gastroenterology 2013.
4. Chen C.Y.H.I., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis b virus dna level. JAMA 2006, 295:65-73.
5. Singal A.K., Salameh H., Kuo Y.F., Fontana R.J. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Alimentary Pharmacology & Therapeutics 2013, 38(2):98-106.
6. Morgan R.L., Baack B., Smith B.D., Yartel A., Pitasi M., Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Annals of Internal Medicine 2013, 158:329-337.
7. Lazo M., Hernaez R., Eberhardt M.S., Bonekamp S., Kamel I., Guallar E., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994. American Journal of Epidemiology 2013, 178(1):38-45.
8. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 2012, 10:1342-1359. e2.
9. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
10. Yang W., Lu Y., Xu Y., Xu L., Zheng W., Wu Y., et al. Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). Journal of Biological Chemistry 2012, 287:40140-40149.
11. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
12. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.-F., et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008, 359:378-390.
13. Chan S.L., Yeo W. Targeted therapy of hepatocellular carcinoma: present and future. Journal of Gastroenterology and Hepatology 2012, 27:862-872.
14. Zender L., Villanueva A., Tovar V., Sia D., Chiang D.Y., Llovet J.M. Cancer gene discovery in hepatocellular carcinoma. Journal of Hepatology 2010, 52:921-929.
15. Abu Dayyeh B.K., Yang M., Fuchs B.C., Karl D.L., Yamada S., Sninsky J.J., et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011, 141:141-149.
16. Tanabe K.K., Lemoine A., Finkelstein D.M., Kawasaki H., Fujii T., Chung R.T., et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008, 299:53-60.
17. Zhong J.H., You X.M., Gong W.F., Ma L., Zhang Y., Mo Q.G., et al. Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis. PloS One 2012, 7:e32159.
18. Liu Y., Poon R.T., Shao W., Sun X., Chen H., Kok T.W., et al. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. Cancer Letters 2007, 248:32-40.
19. Schiffer E., Housset C., Cacheux W., Wendum D., Desbois-Mouthon C., Rey C., et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005, 41:307-314.
20. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128.
21. Boyault S., Rickman D.S., de Reyniès A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52.
22. Calvisi D.F., Wang C., Ho C., Ladu S., Lee S.A., Mattu S., et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011, 140:1071-1083.
23. Yong K.J., Gao C., Lim J.S., Yan B., Yang H., Dimitrov T., et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. The New England Journal of Medicine 2013, 368:2266-2276.
24. Liu G., Jiang S., Wang C., Jiang W., Liu Z., Liu C., et al. Zinc finger transcription factor 191, directly binding to β-catenin promoter, promotes cell proliferation of hepatocellular carcinoma. Hepatology 2012, 55:1830-1839.
25. Feng G.J., Cotta W., Wei X.Q., Poetz O., Evans R., Jarde T., et al. Conditional disruption of Axin1 leads to development of liver tumors in mice. Gastroenterology 2012, 143:1650-1659.
26. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
27. Kong S.-Y., Park J.-W., Lee J.A., Park J.E., Park K.W., Hong E.K., et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology 2007, 46:446-455.
28. Poon R.T., Ng I.O., Lau C., Zhu L.X., Yu W.C., Lo C.M., et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Annals of Surgery 2001, 233:227-235.
29. Ryu S.H., Chung Y.H., Lee H., Kim J.A., Shin H.D., Min H.J., et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology 2008, 47:929-936.
30. Dandri M., Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012, 61:i6-i17.
31. Ganem D., Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. The New England Journal of Medicine 2004, 350:1118-1129.
32. Ganem D., Varmus H.E. The molecular biology of the hepatitis B viruses. Annual Review of Biochemistry 1987, 56:651-693.
33. Yan H., Zhong G., Xu G., He W., Jing Z., Gao Z., et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012, 2012.
34. Levrero M., Pollicino T., Petersen J., Belloni L., Raimondo G., Dandri M. Control of cccDNA function in hepatitis B virus infection. Journal of Hepatology 2009, 51:581-592.
35. Tuttleman J.S., Pourcel C., Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986, 47:451-460.
36. Bertoletti A., Republished Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgraduate Medical Journal 2013, 89:294-304.
37. Thimme R., Wieland S., Steiger C., Ghrayeb J., Reimann K.A., Purcell R.H., et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. Journal of Virology 2003, 77:68-76.
38. Boni C., Fisicaro P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. Journal of Virology 2007, 81:4215-4225.
39. Tujios S.R., Lee W.M. Update in the management of chronic hepatitis B. Current Opinion in Gastroenterology 2013, 29:250-256.
40. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
41. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology 2009, 49:S156-S165.
42. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. British Journal of Haematology 2007, 136:699-712.
43. Chang T.T., Lai C.L., Kew Yoon S., Lee S.S., Coelho H.S., Carrilho F.J., et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51:422-430.
44. Gordon S.C., Krastev Z., Horban A., Petersen J., Sperl J., Dinh P., et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 2013.
45. Beasley R.P., Hwang L.Y., Lin C.C., Chien C.S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981, 2:1129-1133.
46. Nguyen V.T., Law M.G., Dore G.J. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. Journal of Viral Hepatitis 2009, 16:453-463.
47. Poorolajal J., Mahmoodi M., Majdzadeh R., Nasseri-Moghaddam S., Haghdoost A., Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010, 28:623-631.
48. Chang M.-H., Chen C.-J., Lai M.-S., Hsu H.-M., Wu T.-C., Kong M.-S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. New England Journal of Medicine 1997, 336:1855-1859.
49. Loomba R., Liu J., Yang H.I., Lee M.H., Lu S.N., Wang L.Y., et al. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 2013, 11(12). 1636-45.e1-3.
50. Yu M.W., Hsu F.C., Sheen I.S., Chu C.M., Lin D.Y., Chen C.J., et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. American Journal of Epidemiology 1997, 145:1039-1047.
51. Nakamoto Y., Guidotti L.G., Kuhlen C.V., Fowler P., Chisari F.V. Immune pathogenesis of hepatocellular carcinoma. The Journal of Experimental Medicine 1998, 188:341-350.
52. Toan N.L., Song le H., Kremsner P.G., Duy D.N., Binh V.Q., Koeberlein B., et al. Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. Hepatology 2006, 43:1375-1384.
53. Tanaka Y., Mukaide M., Orito E., Yuen M.F., Ito K., Kurbanov F., et al. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. Journal of Hepatology 2006, 45:646-653.
54. Yuan J.M., Ambinder A., Fan Y., Gao Y.T., Yu M.C., Groopman J.D. Prospective evaluation of hepatitis B 1762(T)/1764(A) mutations on hepatocellular carcinoma development in Shanghai, China. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2009, 18:590-594.
55. Sells M.A., Chen M.-L., Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. PNAS 1987, 84:1005-1009.
56. Dandri M., Volz T.K., Lutgehetmann M., Petersen J. Animal models for the study of HBV replication and its variants. Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2005, 34(Suppl 1):S54-S62.
57. Chisari F.V. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 1995, 22:1316-1325.
58. Bissig K.D., Wieland S.F., Tran P., Isogawa M., Le T.T., Chisari F.V., et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. The Journal of Clinical Investigation 2010, 120:924-930.
59. Lutgehetmann M., Mancke L.V., Volz T., Helbig M., Allweiss L., Bornscheuer T., et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 2012, 55:685-694.
60. Li Y., Tang Z.Y., Hou J.X. Hepatocellular carcinoma: insight from animal models. Nature Reviews Gastroenterology & Hepatology 2012, 9:32-43.
61. Shaul Y., Ziemer M., Garcia P.D., Crawford R., Hsu H., Valenzuela P., et al. Cloning and analysis of integrated hepatitis virus sequences from a human hepatoma cell line. Journal of Virology 1984, 51:776-787.
62. Fourel G., Couturier J., Wei Y., Apiou F., Tiollais P., Buendia M.A. Evidence for long-range oncogene activation by hepadnavirus insertion. The EMBO Journal 1994, 13:2526-2534.
63. Fourel G., Trepo C., Bougueleret L., Henglein B., Ponzetto A., Tiollais P., et al. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature 1990, 347:294-298.
64. Shamay M., Agami R., Shaul Y. HBV integrants of hepatocellular carcinoma cell lines contain an active enhancer. Oncogene 2001, 20:6811-6819.
65. Chami M., Gozuacik D., Saigo K., Capiod T., Falson P., Lecoeur H., et al. Hepatitis B virus-related insertional mutagenesis implicates SERCA1 gene in the control of apoptosis. Oncogene 2000, 19:2877-2886.
66. Paterlini-Brechot P., Saigo K., Murakami Y., Chami M., Gozuacik D., Mugnier C., et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003, 22:3911-3916.
67. Sung W.-K., Zheng H., Li S., Chen R., Liu X., Li Y., et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nature Genetics 2012, 44:765-769.
68. Ding D., Lou X., Hua D., Yu W., Li L., Wang J., et al. Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genetics 2012, 8:e1003065.
69. Fujimoto A., Totoki Y., Abe T., Boroevich K.A., Hosoda F., Nguyen H.H., et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nature Genetics 2012, 44:760-764.
70. Murakami Y., Saigo K., Takashima H., Minami M., Okanoue T., Brechot C., et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005, 54:1162-1168.
71. Tu H., Bonura C., Giannini C., Mouly H., Soussan P., Kew M., et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Research 2001, 61:7803-7810.
72. Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. Journal of Gastroenterology 2001, 36:651-660.
73. Wei Y., Neuveut C., Tiollais P., Buendia M.A. Molecular biology of the hepatitis B virus and role of the X gene. Pathologie-biologie 2010, 58:267-272.
74. Bouchard M.J., Wang L.H., Schneider R.J. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001, 294:2376-2378.
75. Zoulim F., Saputelli J., Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. Journal of Virology 1994, 68:2026-2030.
76. Hepatitis Koike K. B virus X gene is implicated in liver carcinogenesis. Cancer Letters 2009, 286:60-68.
77. Hohne M., Schaefer S., Seifer M., Feitelson M.A., Paul D., Gerlich W.H. Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA. The EMBO Journal 1990, 9:1137-1145.
78. Seifer M., Hohne M., Schaefer S., Gerlich W.H. In vitro tumorigenicity of hepatitis B virus DNA and HBx protein. Journal of Hepatology 1991, 13(Suppl 4):S61-S65.
79. Kim C.M., Koike K., Saito I., Miyamura T., Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991, 351:317-320.
80. Yu D.Y., Moon H.B., Son J.K., Jeong S., Yu S.L., Yoon H., et al. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. Journal of Hepatology 1999, 31:123-132.
81. Zhang T., Zhang J., You X., Liu Q., Du Y., Gao Y., et al. Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology 2012, 56:2051-2059.
82. Maguire H., Hoeffler J., Siddiqui A.H.B.V. X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 1991, 252:842-844.
83. Chan C., Wang Y., Chow P.K.H., Chung A.Y.F., Ooi L.L.P.J., Lee C.G. Altered binding site selection of p53 transcription cassettes by hepatitis B virus X protein. Molecular and Cellular Biology 2013, 33:485-497.
84. Lee H., Kim H.T., Yun Y. Liver-specific enhancer II is the target for the p53-mediated inhibition of hepatitis B viral gene expression. The Journal of Biological Chemistry 1998, 273:19786-19791.
85. Lee S.G., Rho H.M. Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene 2000, 19:468-471.
86. van Breugel P.C., Robert E.I., Mueller H., Decorsiere A., Zoulim F., Hantz O., et al. Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates. Hepatology 2012, 56:2116-2124.
87. Hodgson A.A.J., Hyser J.M., Keasler V.V., Cang Y., Slagle B.L. Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication. Virology 2012, 426:73-82.
88. Leupin O., Bontron S., Schaeffer C., Strubin M. Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death. Journal of Virology 2005, 79:4238-4245.
89. Bontron S., Lin-Marq N., Strubin M. Hepatitis B virus X protein associated with UV-DDB1 induces cell death in the nucleus and is functionally antagonized by UV-DDB2. Journal of Biological Chemistry 2002, 277:38847-38854.
90. Becker S.A., Lee T.-H., Butel J.S., Slagle B.L. Hepatitis B virus X protein interferes with cellular DNA repair. Journal of Virology 1998, 72:266-272.
91. Martin-Lluesma S., Schaeffer C., Robert E.I., van Breugel P.C., Leupin O., Hantz O., et al. Hepatitis B virus X protein affects S phase progression leading to chromosome segregation defects by binding to damaged DNA binding protein 1. Hepatology 2008, 48:1467-1476.
92. Elmore L.W., Hancock A.R., Chang S.-F., Wang X.W., Chang S., Callahan C.P., et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proceedings of the National Academy of Sciences 1997, 94:14707-14712.
93. Truant R., Antunovic J., Greenblatt J., Prives C., Cromlish J.A. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. Journal of Virology 1995, 69:1851-1859.
94. Su F., Schneider R.J. Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins. Journal of Virology 1996, 70:4558-4566.
95. Waris G., Huh K.W., Siddiqui A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress. Molecular and Cellular Biology 2001, 21:7721-7730.
96. Yun C., Um H.R., Jin Y.H., Wang J.H., Lee M.O., Park S., et al. NF-kappaB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. Cancer Letters 2002, 184:97-104.
97. Benn J., Schneider R.J. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:10350-10354.
98. Lee Y.I., Kang-Park S., Do S.-I., Lee Y.I. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. Journal of Biological Chemistry 2001, 276:16969-16977.
99. Klein N.P., Schneider R.J. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Molecular and Cellular Biology 1997, 17:6427-6436.
100. Klein N.P., Bouchard M.J., Wang L.H., Kobarg C., Schneider R.J. Src kinases involved in hepatitis B virus replication. The EMBO Journal 1999, 18:5019-5027.
101. Cha M.Y., Kim C.M., Park Y.M., Ryu W.S. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology 2004, 39:1683-1693.
102. Hsieh A., Kim H.S., Lim S.O., Yu D.Y., Jung G. Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/beta-catenin signaling. Cancer Letters 2011, 300:162-172.
103. Ding Q., Xia W., Liu J.C., Yang J.Y., Lee D.F., Xia J., et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Molecular Cell 2005, 19:159-170.
104. Tian Y., Yang W., Song J., Wu Y., Ni B.H.B.V. X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis. Molecular and Cellular Biology 2013.
105. Jung J.K., Arora P., Pagano J.S., Jang K.L. Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Research 2007, 67:5771-5778.
106. Tong A., Gou L., Lau Q.C., Chen B., Zhao X., Li J., et al. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis B virus X protein. Journal of Proteome Research 2009, 8:1037-1046.
107. Zhu Y.Z., Zhu R., Fan J., Pan Q., Li H., Chen Q., et al. Hepatitis B virus X protein induces hypermethylation of p16(INK4A) promoter via DNA methyltransferases in the early stage of HBV-associated hepatocarcinogenesis. Journal of Viral Hepatitis 2010, 17:98-107.
108. Kong G., Zhang J., Zhang S., Shan C., Ye L., Zhang X. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PloS One 2011, 6:e19518.
109. Yang L., Ma Z., Wang D., Zhao W., Chen L., Wang G. MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma. Cancer Biology & Therapy 2010, 9:803-808.
110. Yuan K., Lian Z., Sun B., Clayton M.M., Ng I.O., Feitelson M.A. Role of miR-148a in hepatitis B associated hepatocellular carcinoma. PloS One 2012, 7:e35331.
111. Zhang X., Liu S., Hu T., Liu S., He Y., Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 2009, 50:490-499.
112. Song K., Han C., Zhang J., Lu D., Dash S., Feitelson M., et al. Epigenetic regulation of miR-122 by PPARgamma and hepatitis B virus X protein in hepatocellular carcinoma cells. Hepatology 2013, 58(5):1681-1692.
113. Hsu S.H., Wang B., Kota J., Yu J., Costinean S., Kutay H., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. The Journal of Clinical Investigation 2012, 122:2871-2883.
114. Liu N., Zhang J., Jiao T., Li Z., Peng J., Cui Z., et al. Hepatitis B virus inhibits apoptosis of hepatoma cells by sponging the MicroRNA 15a/16 cluster. Journal of Virology 2013, 87:13370-13378.
115. Wang Y., Jiang L., Ji X., Yang B., Zhang Y., Fu X.-D. Hepatitis B viral RNA directly mediates down-regulation of the tumor suppressor MicroRNA miR-15a/miR-16-1 in hepatocytes. Journal of Biological Chemistry 2013, 288:18484-18493.
116. Houghton M. The long and winding road leading to the identification of the hepatitis C virus. Journal of Hepatology 2009, 51:939-948.
117. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology 2006, 45:529-538.
118. Tanaka Y., Hanada K., Orito E., Akahane Y., Chayama K., Yoshizawa H., et al. Molecular evolutionary analyses implicate injection treatment for schistosomiasis in the initial hepatitis C epidemics in Japan. Journal of Hepatology 2005, 42:47-53.
119. Tanaka H., Imai Y., Hiramatsu N., Ito Y., Imanaka K., Oshita M., et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Annals of Internal Medicine 2008, 148:820-826.
120. Salomon J.A., Weinstein M.C., Hammitt J.K., Goldie S.J. Empirically calibrated model of hepatitis C virus infection in the United States. American Journal of Epidemiology 2002, 156:761-773.
121. Lok A.S., Seeff L.B., Morgan T.R., di Bisceglie A.M., Sterling R.K., Curto T.M., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136:138-148.
122. Ikeda K., Marusawa H., Osaki Y., Nakamura T., Kitajima N., Yamashita Y., et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Annals of Internal Medicine 2007, 146:649-656.
123. Lok A.S., Everhart J.E., Di Bisceglie A.M., Kim H.Y., Hussain M., Morgan T.R. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 2011, 54:434-442.
124. Baffy G., Brunt E.M., Caldwell S.H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. Journal of Hepatology 2012, 56:1384-1391.
125. Yang J.D., Harmsen W.S., Slettedahl S.W., Chaiteerakij R., Enders F.T., Therneau T.M., et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 2011, 9:617-623. e1.
126. Ishiguro S., Inoue M., Tanaka Y., Mizokami M., Iwasaki M., Tsugane S. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. European Journal of Cancer Prevention: The Official Journal of the European Cancer Prevention Organisation (ECP) 2009, 18:26-32.
127. Kumada T., Toyoda H., Kiriyama S., Sone Y., Tanikawa M., Hisanaga Y., et al. Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels. Journal of Hepatology 2009, 50:729-735.
128. Lee M.H., Yang H.I., Lu S.N., Jen C.L., Yeh S.H., Liu C.J., et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2010, 28:4587-4593.
129. Cardoso A.C., Moucari R., Figueiredo-Mendes C., Ripault M.P., Giuily N., Castelnau C., et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. Journal of Hepatology 2010, 52:652-657.
130. Morgan T.R., Ghany M.G., Kim H.Y., Snow K.K., Shiffman M.L., De Santo J.L., et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010, 52:833-844.
131. Yu M.L., Lin S.M., Chuang W.L., Dai C.Y., Wang J.H., Lu S.N., et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antiviral Therapy 2006, 11:985-994.
132. Luedde T., Schwabe R.F. NF-kappaB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology 2011, 8:108-118.
133. Weber A., Boege Y., Reisinger F., Heikenwalder M. Chronic liver inflammation and hepatocellular carcinoma: persistence matters. Swiss Medical Weekly 2011, 141:w13197.
134. Jesudian A.B., de Jong Y.P., Jacobson I.M. Emerging therapeutic targets for hepatitis C virus infection. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 2013, 11:612-619. e1.
135. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285:110-113.
136. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
137. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Medicine 2005, 11:791-796.
138. Kato T., Furusaka A., Miyamoto M., Date T., Yasui K., Hiramoto J., et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. Journal of Medical Virology 2001, 64:334-339.
139. Li Y.P., Ramirez S., Gottwein J.M., Scheel T.K., Mikkelsen L., Purcell R.H., et al. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:E1101-E1110.
140. Li Y.P., Ramirez S., Jensen S.B., Purcell R.H., Gottwein J.M., Bukh J. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:19757-19762.
141. Yi M., Lemon S.M. Genotype 1a HCV (H77S) infection system. Methods in Molecular Biology 2009, 510:337-346.
142. Rice C.M. New insights into HCV replication: potential antiviral targets. Topics in Antiviral Medicine 2011, 19:117-120.
143. Lanford R.E., Lemon S.M., Walker C. The chimpanzee model of hepatitis C infections and small animal surrogates. Hepatitis C Antiviral Drug Discovery & Development 2011, 99-132.
144. Rusyn I., Lemon S.M. Mechanisms of HCV-induced liver cancer: what did we learn from in vitro and animal studies?. Cancer Letters 2013, pii:S0304-3835(13)00493-X [Epub ahead of print]. 10.1016/j.canlet.2013.06.028.
145. Lerat H., Higgs M., Pawlotsky J.M. Animal models in the study of hepatitis C virus-associated liver pathologies. Expert Review of Gastroenterology & Hepatology 2011, 5:341-352.
146. Tsutsumi T., Suzuki T., Moriya K., Yotsuyanagi H., Shintani Y., Fujie H., et al. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 2002, 304:415-424.
147. Klopstock N., Katzenellenbogen M., Pappo O., Sklair-Levy M., Olam D., Mizrahi L., et al. HCV tumor promoting effect is dependent on host genetic background. PloS One 2009, 4:e5025.
148. Furutani T., Hino K., Okuda M., Gondo T., Nishina S., Kitase A., et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006, 130:2087-2098.
149. Meuleman P., Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Research 2008, 80:231-238.
150. Joyce M.A., Walters K.A., Lamb S.E., Yeh M.M., Zhu L.F., Kneteman N., et al. HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLoS Pathogens 2009, 5:e1000291.
151. Washburn M.L., Bility M.T., Zhang L., Kovalev G.I., Buntzman A., Frelinger J.A., et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011, 140:1334-1344.
152. Alam S.S., Nakamura T., Naganuma A., Nozaki A., Nouso K., Shimomura H., et al. Hepatitis C virus quasispecies in cancerous and noncancerous hepatic lesions: the core protein-encoding region. Acta Medica Okayama 2002, 56:141-147.
153. Sobesky R., Feray C., Rimlinger F., Derian N., Dos Santos A., Roque-Afonso A.M., et al. Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection. Hepatology 2007, 46:1704-1712.
154. McGivern D.R., Lemon S.M. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011, 30:1969-1983.
155. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nature Medicine 2013, 19:859-868.
156. Yu G.Y., He G., Li C.Y., Tang M., Grivennikov S., Tsai W.T., et al. Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production. Molecular Cell 2012, 48:313-321.
157. Okuda M., Li K., Beard M.R., Showalter L.A., Scholle F., Lemon S.M., et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366-375.
158. Korenaga M., Wang T., Li Y., Showalter L.A., Chan T., Sun J., et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. The Journal of Biological Chemistry 2005, 280:37481-37488.
159. Munakata T., Nakamura M., Liang Y., Li K., Lemon S.M. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:18159-18164.
160. Kao C.F., Chen S.Y., Chen J.Y., Wu Lee Y.H. Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. Oncogene 2004, 23:2472-2483.
161. Deng L., Nagano-Fujii M., Tanaka M., Nomura-Takigawa Y., Ikeda M., Kato N., et al. NS3 protein of Hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. The Journal of General Virology 2006, 87:1703-1713.
162. Majumder M., Ghosh A.K., Steele R., Ray R., Ray R.B. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. Journal of Virology 2001, 75:1401-1407.
163. Park C.Y., Choi S.H., Kang S.M., Kang J.I., Ahn B.Y., Kim H., et al. Nonstructural 5A protein activates beta-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis. Journal of Hepatology 2009, 51:853-864.
164. Street A., Macdonald A., McCormick C., Harris M. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription. Journal of Virology 2005, 79:5006-5016.
165. Milward A., Mankouri J., Hepatitis Harris M. C virus NS5A protein interacts with beta-catenin and stimulates its transcriptional activity in a phosphoinositide-3 kinase-dependent fashion. The Journal of General Virology 2010, 91:373-381.
166. Ariumi Y., Kuroki M., Dansako H., Abe K.-I., Ikeda M., Wakita T., et al. The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication. Journal of Virology 2008, 82:9639-9646.
167. Lai C.-K., Jeng K.-S., Machida K., Cheng Y.-S., Hepatitis Lai M.M.C. C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation. Virology 2008, 370:295-309.
168. Choi S.H., Hwang S.B. Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein. The Journal of Biological Chemistry 2006, 281:7468-7478.
169. Pavio N., Battaglia S., Boucreux D., Arnulf B., Sobesky R., Hermine O., et al. Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-[beta] pathway. Oncogene 2005, 24:6119-6132.
170. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309:1577-1581.
171. Janssen H.L.A., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., et al. Treatment of HCV infection by targeting MicroRNA. New England Journal of Medicine 2013, 368:1685-1694.
172. Tsai W.C., Hsu S.D., Hsu C.S., Lai T.C., Chen S.J., Shen R., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. The Journal of Clinical Investigation 2012, 122:2884-2897.
173. Trebicka J., Anadol E., Elfimova N., Strack I., Roggendorf M., Viazov S., et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. Journal of Hepatology 2013, 58:234-239.
174. Sarasin-Filipowicz M., Krol J., Markiewicz I., Heim M.H., Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nature Medicine 2009, 15:31-33.
175. Han Z.G. Functional genomic studies: insights into the pathogenesis of liver cancer. Annual Review of Genomics and Human Genetics 2012, 13:171-205.